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dard first-line cytotoxic treatment for patients with 
metastatic castrate-resistant prostate cancer (mCRPC). 
Today, several new treatment options are available for 
patients with tumor progression after first-line docetaxel: 
Abiraterone, enzalutamide, cabazitaxel, sipuleucel-T im-
munotherapy, and the radionuclide radium-223. However, 
despite the evolving scenario in CRPC treatment, the 
optimal sequencing of the innovative therapies remains 
unclear. The reintroduction of docetaxel at the occurrence 
of disease progression after a drug holiday (docetaxel 
rechallenge) was often proposed, and this chemoth-
erapeutic agent showed to maintain antitumor activity 
in mCRPC patients. Docetaxel rechallenge may still 
constitute a valid treatment option mainly for patients 
with favorable response to first-line docetaxel, at least > 
3 mo progression-free interval, age less than 75 years, 
good performance status, and acceptable docetaxel 
toxicity. The risk of cumulative toxicity must be evaluated, 
since sensory neuropathy, nail disorders and fatigue 
might occur on docetaxel rechallenge. 
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Core tip: New treatment options are currently available 
for metastatic castrate-resistant prostate cancer 
(mCRPC) patients after first-line chemotherapy with 
docetaxel. The actual role of docetaxel rechallenge in 
the evolving scenario of mCRPC treatment is discussed 
in this editorial. 
Petrioli R, Francini E, Roviello G. Is there still a place for 
docetaxel rechallenge in prostate cancer? World J Clin Oncol 
2015; 6(5): 99-103  Available from: URL: http://www.wjgnet.
com/2218-4333/full/v6/i5/99.htm  DOI: http://dx.doi.org/10.5306/
wjco.v6.i5.99
Is there still a place for docetaxel rechallenge in prostate 
cancer?
Roberto Petrioli, Edoardo Francini, Giandomenico Roviello
Roberto Petrioli, Giandomenico Roviello, Medical Oncology 
Unit, Department of Medicine, Surgery and Neurosciences, 
University of Siena, 53100 Siena, Italy
Edoardo Francini, Medical Oncology Unit, Policlinico Umberto 
I Hospital, University of Rome, 00161 Rome, Italy
Author contributions: Petrioli R and Roviello G contributed to 
study design and writing; Edoardo F contributed to writing.
Conflict-of-interest statement: No author has actual or 
potential conflicts of interest, including any financial, personal 
or other relationships with other people or organizations within 
three years of beginning the submitted work that could influence, 
or be perceived to influence, their work. 
Open-Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Correspondence to: Roberto Petrioli, MD, Medical Oncology 
Unit, Department of Medicine, Surgery and Neurosciences, 




Received: March 11, 2015 
Peer-review started: March 18, 2015 
First decision: June 3, 2015
Revised: June 15, 2015 
Accepted: July 24, 2015
Article in press: July 27, 2015
Published online: October 10, 2015
Abstract
Three-weekly docetaxel plus prednisone is the stan-
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INTRODUCTION
From 2004, three-weekly docetaxel plus prednisone is 
the standard first-line cytotoxic treatment for patients 
with metastatic castrate-resistant prostate cancer 
(mCRPC)[1,2]. In TAX 327 trial, which compared 3-weekly 
docetaxel plus prednisone vs mitoxantrone plus pre-
dnisone, 45% of patients receiving docetaxel and 
prednisone achieved ≥ 50% prostatic-specific antigen 
(PSA) reduction, and the median duration of PSA 
response was 7.7 mo. The patients received a maximum 
of 8-10 docetaxel cycles, and more that one third of 
them discontinued chemotherapy without evidence 
of disease progression. At 4-year follow-up, 3-weekly 
docetaxel plus prednisone maintained a statistically 
significant advantage in overall survival (OS) compared 
to mitoxantrone plus prednisone (19.2 mo vs 16.3 mo, 
P = 0.004)[3]. 
The reintroduction of docetaxel at the occurrence 
of disease progression after a drug holiday was often 
proposed in mCRPC patients, and the drug showed 
to maintain antitumor activity[4-6]. The truly docetaxel 
rechallenge consists in the reintroduction of the drug 
in patients responding to first-line docetaxel who dis-
continued chemotherapy without evidence of disease 
progression. Although significant advantages in terms 
of OS were not demonstrated, all studies reported > 
25% PSA response on docetaxel rechallenge in patients 
achieving an initial good response to first-line treatment 
with the same drug[4-7]. 
SUGGESTED ELIGIBILITY CRITERIA FOR 
DOCETAXEL RECHALLENGE
Docetaxel has been the first drug to report a survival 
benefit for mCRPC patients. Although these men are 
usually elderly and with concomitant comorbidities, some 
of them still have an acceptable performance status 
and might be proposed for another treatment after 
docetaxel failure. Today several new treatment options 
are available for patients with tumor progression after 
first-line docetaxel: abiraterone, enzalutamide, cabazit-
axel, sipuleucel-T immunotherapy, and the radionuclide 
radium-223[8-12]. 
Abiraterone acetate, a selective irreversible inhibi-
tor of cytochrome P-450c17, prolonged OS in chemo-
therapy-naïve or docetaxel-pretreated patients[8,13]. 
Enzalutamide, a novel androgen receptor signaling 
inhibitor, significantly prolonged OS and improved quality 
of life compared to placebo in men with post-docetaxel 
CRPC[9]. Enzalutamide was recently approved also in 
pre-docetaxel patients[14].
Cabazitaxel, a second-generation taxane, achieved 
a statistically significant improvement in OS when 
added to prednisone vs mitoxantrone plus prednisone 
in mCRPC patients[10]. Sipuleucel-T, an active cellular 
immunotherapy, prolonged OS among asymptomatic 
mCRPC patients[11], and Radium-223, which has high 
bone affinity, improved OS and time to first skeletal-
related event[12]. Despite the availability of these new 
agents in mCRPC patients, their optimal sequencing 
remains unclear[15].
The possibility of a docetaxel rechallenge has been 
largely limited by the introduction of abiraterone, 
enzalutamide and cabazitaxel in the treatment of CRPC 
patients. Neverthless, it must be considered that the 
reintroduction of docetaxel can reduce the possibility 
to administer to the patients one of the new available 
treatment options. However, a docetaxel rechallenge 
therapy may be a cheaper option considering the budget 
impact on health plans of new anticancer agents[16]. 
Furthermore, the situation is actually complicated by 
recent trials which might led to early prescription of 
docetaxel in combination with androgen-deprivation 
therapy, or for the new indications of abiraterone 
and enzalutamide in pre-docetaxel patients[13,14,17]. In 
this setting, some clinical reports suggested a cross-
resistance when first-line chemotherapy with docetaxel 
was administered after the new hormonal agent 
abiraterone, while there were very few experiences about 
docetaxel rechallenge after failure to abiraterone or other 
agents[18-20].
The results of the ongoing randomized phase Ⅱ 
study CANTATA (EudraCT 2012-003835-40) comparing 
cabazitaxel with docetaxel rechallenge will add useful 
informations about the role of docetaxel rechallenge in 
the mCRPC new agents-era.
Docetaxel rechallenge may still have a role in 
mCRPC, but a carefull selection of patients has to be 
performed. Most studies reported that ≥ 50% PSA 
response to first-line docetaxel was the main predictive 
factor for the favorable outcome on the reintroduction 
of the same drug. A progression free-interval (PFI) of 
> 6 mo after first-line docetaxel was associated with 
high fequency of good PSA responses and symptomatic 
responses on docetaxel rechallenge in a large retros-
pective study, and encouraging 20.4 mo median OS was 
reported[21]. Another study described a longer median 
PFS (6.3 mo vs 3.4 mo) and median OS (19.4 mo vs 
12.8 mo) with docetaxel rechallenge in mCRPC patients 
progressing at > 3 mo after the last docetaxel cycle with 
respect to those progressing within 3 mo[22]. In a study 
of 46 patients with CRPC rechallenged with docetaxel, 
the PSA response was 66%, and the median OS was 
32 mo. In this study a docetaxel rechallenge was safely 
repeated sveral times, and the good responders had a 
median PFI of 6 mo[7].
On the other hand, it was reported that PFI < 3 
mo was associated with no benefit from docetaxel 
rechallenge, probably because of early development of 
complex mechanisms of resistance to the drug[23]. 
Available findings indicate that docetaxel rechallenge 
might still constitute a valid treatment option, and some 
eligibility criteria may be suggested: good response 
to first-line docetaxel, at least > 3 mo PFI, age less 
than 75 years, and acceptable docetaxel toxicity (Table 
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1). On the other hand, very elderly patients and/or 
men with worsened performance status could benefit 
from less aggressive treatment options. Furthermore, 
since the chemotherapy agent cabazitaxel shows low 
incidence of severe sensory neuropathy, this drug may 
be a valid treatment choice for patients who exhibit 
unacceptable toxicity to docetaxel[10]. 
Another intriguing treatment strategy, especially 
for patients with PFI 3-6 mo, might be to combine 
docetaxel rechallenge with another agent which might 
help to overcome the resistance to docetaxel. Among 
chemotherapeutic agents which were investigated, 
epirubicin resulted feasible and tolerable when combined 
with docetaxel on a weekly schedule[24]. A randomized 
phase Ⅱ study suggested an advantage in PSA response, 
PFS, and OS for the combination of docetaxel and 
epirubicin compared with docetaxel alone in advanced 
CRPC patients[25]. In a recent clinical study, our research 
team reported encouraging results with rechallenge 
of docetaxel combined with weekly epirubicin in 26 
men with advanced CRPC following progression on 
docetaxel and abiraterone acetate, with PSA response 
in 26.9% of patients, 4.4 mo PFS, and 10.7 median 
OS[26]. Among the subjects who were symptomatic at 
baseline, pain was reduced in 9 patients (38.1%) with 
a significant decrease in analgesic use. The weekly 
epirubicin/doxorubicin treatment was well tolerated: 
grade 3 neutropenia occurred in 19.2% of patients, 
and no grade 4 toxicity or congestive heart failure was 
observed.
These encouraging results may also suggest that 
abiraterone treatment after docetaxel failure does not 
reduce the efficacy of a delayed docetaxel rechallenge. 
Larger studies should be performed to investigate if 
epirubicin or other agents may play a role in restoring 
the sensitivity and reversing the resistance to docetaxel 
in patients who were previously poor-responders to the 
same drug. 
Despite the addition of a drug to docetaxel rechall-
enge might led to overcome the resistance to docetaxel, 
the risk of eventual increase in the occurrence of adverse 
events must be considered, too[27-29]. Moreover, sensory 
neuropathy, nail disorders and fatigue might occur on 
docetaxel rechallenge[6,7,21].
 Though the feasibility and activity of docetaxel 
rechallenge in mCRPC patients have been demonstrated 
in several studies before the new agents-era, very few 
data are available about the reintroduction of the drug 
in heavily pretreated subjects. It might hypothesized 
that in mCRPC patients with PFI 3-6 mo a delayed 
rechallenge by intercalation of a non-docetaxel treatment 
might be effective, with possible restoring of sensitivity 
to the drug. In this setting, in other tumors such as 
relapsed ovarian cancer, the PFI prolongation by intercal-
ation by an effective non-platinum regimen resulted in 
survival advantage with subsequent platinum-based 
regimens[30,31]. 
Another interesting point is that docetaxel rechallenge 
on weekly schedule might be offered, especially for 
mCRPC patients with some degree of toxicity during 
3-weekly docetaxel. Neverthless, a few small experi-
ences suggested that weekly docetaxel schedule might 
be effective in patients not-responding to first-line 
3-weekly docetaxel[7,32]. In conclusion, as we all await 
additional studies to clarify the optimal sequencing of the 
new available agents in mCRPC, docetaxel rechallenge 
may have still a role for well selected patients.
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PFI > 3-6 mo
 > 50% PSA response to first-line docetaxel
No cumulative docetaxel-toxicity
Age < 75 yr
ECOG PS 0-1
Table 1  Main eligibility criteria for docetaxel rechallenge in 
metastatic castrate-resistant prostate cancer patients
PFI: Progression free-interval; PSA: Prostatic-specific antigen.
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